ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
45 announcements
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
Jagsonpal Pharmaceuticals has designated Mr. Balmukund Keshav (DGM-IT) and Mr. Sanjay Singhal (GM-CQA & Regulatory Affairs) as Senior Management Personnel, effective July 29, 2026.
Jagsonpal Pharmaceuticals has granted 1,20,000 employee stock options under its 2022 ESOP plan. The options carry an exercise price of Rs. 179.25 each.
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals has scheduled its 47th AGM for September 18, 2026. The company also confirmed September 04, 2026, as the record date for its previously recommended dividend.
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
Jagsonpal Pharmaceuticals will hold a board meeting on July 29, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Jagsonpal Pharmaceuticals has completed the acquisition of an 85% equity stake in Aequitas Healthcare. This follows initial acquisition intimations made in June 2026.
Jagsonpal Pharmaceuticals allotted 94,000 equity shares under its ESOP scheme. Consequently, the company's paid-up share capital increased to Rs. 13.18 Crore.
Jagsonpal Pharmaceuticals allotted 94,000 equity shares under its 2022 ESOP plan. This exercise increased the paid-up share capital to Rs. 13.19 Crore.
Jagsonpal Pharmaceuticals completed the acquisition of a 69.77% stake in Aequitas Healthcare, turning it into a subsidiary. No monetary value was disclosed.
Jagsonpal Pharmaceuticals is acquiring an 85% stake in Aequitas Healthcare for ₹20.78 Crore. This strategic move provides access to hospital channels and institutional doctor networks.
Jagsonpal Pharmaceuticals will acquire an 85% stake in Aequitas Healthcare for ₹20.8 Crore. The transaction marks its strategic entry into the hospital segment.
Jagsonpal Pharmaceuticals appointed Mr. Anil Kumar Matai as a Non-Executive Independent Director. His five-year term commenced on June 25, 2026.
Jagsonpal Pharmaceuticals allotted 2,96,320 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to 6,58,35,470 shares.
Jagsonpal Pharmaceuticals allotted 2,96,320 equity shares following ESOP exercises valued at approximately ₹2.92 Crore. This increases the company's total paid-up capital to ₹13.17 Crore.
Jagsonpal Pharmaceuticals extinguished 16,00,000 equity shares following a successful buyback via tender offer. The post-buyback paid-up capital now stands at Rs. 13.11 Crore.
Jagsonpal Pharmaceuticals filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The auditor reported nil non-compliances and no regulatory fines.
Jagsonpal Pharmaceuticals completed a ₹40 Crore equity share buyback via the tender offer route. The company repurchased 1,600,000 shares, increasing promoter holding to 69.36%.
Mrs. Pallavi Dinodia Gupta resigned as Independent Director from Jagsonpal Pharmaceuticals effective May 18, 2026. She cited personal reasons and professional commitments for stepping down.
Jagsonpal Pharmaceuticals Ltd announced a share buyback of 16,00,000 equity shares via a tender offer at ₹250 per share. The total buyback size is capped at ₹40 Crore. The offer opens on May 8, 2026, and closes on May 14, 2026, aimed at returning capital to shareholders.
Jagsonpal Pharmaceuticals Limited announced a buyback of up to 16,00,000 equity shares at ₹250 per share, totalling ₹40 Crore. The buyback, representing 2.38% of paid-up capital, opens on May 08, 2026, and closes on May 14, 2026.
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.
Jagsonpal Pharmaceuticals Limited announced a buyback of up to 16,00,000 equity shares at ₹250 per share, totaling ₹40 Crore. The buyback will be conducted via a tender offer on a proportionate basis. The company has fixed May 4, 2026, as the record date to determine eligible shareholders for the offer.